Journal ArticleDOI
Pancreatic cancer surgery in the new millennium: better prediction of outcome.
Werner Hartwig,Thilo Hackert,Ulf Hinz,Alexander Gluth,Frank Bergmann,Oliver Strobel,Markus W. Büchler,Jens Werner +7 more
Reads0
Chats0
TLDR
A newly defined prognostic profiling including the revised R1-definition discriminates survival of patients with resectable pancreatic adenocarcinoma better than the AJCC staging system, and may be of particular relevance for patient-adjusted therapy in the heterogeneous group of AJCC stage II tumors.Abstract:
Background:Surgery is the only therapy with potentially curative intention in pancreatic cancer. This analysis aimed to determine prognostic parameters in a patient cohort with resected pancreatic adenocarcinoma with a special focus on the revised R1-definition.Methods:Between October 2001 and Augusread more
Citations
More filters
Journal ArticleDOI
Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).
Maximilian Bockhorn,Faik G. Uzunoglu,Mustapha Adham,Clem W. Imrie,Miroslav Milicevic,Aken A. Sandberg,Horacio J. Asbun,Claudio Bassi,Markus W. Büchler,Richard Charnley,Kevin C. Conlon,Laureano Fernandez Cruz,Christos Dervenis,Abe Fingerhutt,Helmut Friess,Dirk J. Gouma,Werner Hartwig,Keith D. Lillemoe,Marco Montorsi,John P. Neoptolemos,Shailesh V. Shrikhande,Kyoichi Takaori,William Traverso,Yogesh K. Vashist,Charles M. Vollmer,Charles J. Yeo,Jakob R. Izbicki +26 more
TL;DR: Current evidence justifies portomesenteric venous resection in patients with BRPC, and a new classification of extrahepatic mesentericoportal ven Mous resections is proposed by the ISGPS.
Journal ArticleDOI
Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).
Johanna A. M. G. Tol,Dirk J. Gouma,Claudio Bassi,Christos Dervenis,Marco Montorsi,Mustapha Adham,Åke Andrén-Sandberg,Horacio J. Asbun,Maximilian Bockhorn,Markus W. Büchler,Kevin C. Conlon,Laureano Fernández-Cruz,Abe Fingerhut,Abe Fingerhut,Helmut Friess,Werner Hartwig,Jakob R. Izbicki,Keith D. Lillemoe,Miroslav Milicevic,John P. Neoptolemos,Shailesh V. Shrikhande,Charles M. Vollmer,Charles J. Yeo,Richard Charnley +23 more
TL;DR: Standard lymphadenectomy for pancreatoduodenectomy should strive to resect Ln stations no. 5, 6, 8a, 12b1,12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b, for cancers of the body and tail of the pancreas, removal of stations 10, 11, and 18 is standard.
Journal ArticleDOI
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.
Thilo Hackert,Milena Sachsenmaier,Ulf Hinz,Lutz Schneider,Christoph W. Michalski,Christoph Springfeld,Oliver Strobel,Dirk Jäger,Alexis Ulrich,Markus W. Büchler +9 more
TL;DR: Folfirinox seems to be the most effective protocol resulting in a significantly better secondary resection rate and overall survival than other treatments and should be considered in all patients fit for this regimen and consecutive surgical exploration.
Journal ArticleDOI
Improvement of surgical results for pancreatic cancer.
TL;DR: With increasing evidence on surgical and perioperative aspects of pancreatic cancer therapy, short-term and long-term outcomes of resectables and borderline resectable pancreatic cancers are improving.
Journal ArticleDOI
Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality
R. F. de Wilde,Marc G. Besselink,I. van der Tweel,I.H.J.T. de Hingh,C.H.J. van Eijck,Cornelis H. C. Dejong,Robert J. Porte,D. J. Gouma,O.R.C. Busch,I. Q. Molenaar +9 more
TL;DR: Analysis of changes in hospital volumes and in‐hospital mortality after PD in the Netherlands between 2004 and 2009 found that nationwide centralization of pancreaticoduodenectomy affected mortality.
References
More filters
Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
Journal ArticleDOI
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle,Stefan Post,Peter Neuhaus,Klaus Gellert,Jan M. Langrehr,Karsten Ridwelski,Harald Schramm,J. Fahlke,Carl Zuelke,Christof Burkart,Klaus Gutberlet,E. Kettner,Harald Schmalenberg,Karin Weigang-Koehler,Wolf O. Bechstein,Marco Niedergethmann,Ingo G.H. Schmidt-Wolf,Lars Roll,Bernd Doerken,Hanno Riess +19 more
TL;DR: The results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas by significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone.
Journal ArticleDOI
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial
John P. Neoptolemos,Deborah D. Stocken,Claudio Bassi,Paula Ghaneh,David Cunningham,David Goldstein,Robert Padbury,Malcolm J. Moore,Steven Gallinger,Christophe Mariette,Moritz N. Wente,Jakob R. Izbicki,Helmut Friess,Markus M. Lerch,Christos Dervenis,Attila Oláh,Giovanni Butturini,Ryuichiro Doi,Pehr Lind,David Smith,Juan W. Valle,Daniel H. Palmer,John A. C. Buckels,Joyce Thompson,Colin J. McKay,Charlotte L. Rawcliffe,Markus W. Büchler +26 more
TL;DR: Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival in patients with completely resected pancreatic cancer.
Journal ArticleDOI
One thousand consecutive pancreaticoduodenectomies.
TL;DR: Pancreaticoduodenectomy has become an effective operation for pancreatic cancer in those patients in whom their tumor is margin negative and node negative, and Operative time, blood loss, and length of stay have dropped substantially.
Journal ArticleDOI
Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Updated Experience
Taylor A. Sohn,Charles J. Yeo,John L. Cameron,Ralph H. Hruban,Noriyoshi Fukushima,Kurtis A. Campbell,Keith D. Lillemoe +6 more
TL;DR: IPMNs continue to be recognized with increasing frequency and five-year survival for those patients following resection of IPMNs with invasive cancer (43%) is improved compared with those patients with resected pancreatic ductal adenocarcinoma-in situ (CIS).
Related Papers (5)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle,Stefan Post,Peter Neuhaus,Klaus Gellert,Jan M. Langrehr,Karsten Ridwelski,Harald Schramm,J. Fahlke,Carl Zuelke,Christof Burkart,Klaus Gutberlet,E. Kettner,Harald Schmalenberg,Karin Weigang-Koehler,Wolf O. Bechstein,Marco Niedergethmann,Ingo G.H. Schmidt-Wolf,Lars Roll,Bernd Doerken,Hanno Riess +19 more
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial
John P. Neoptolemos,Deborah D. Stocken,Claudio Bassi,Paula Ghaneh,David Cunningham,David Goldstein,Robert Padbury,Malcolm J. Moore,Steven Gallinger,Christophe Mariette,Moritz N. Wente,Jakob R. Izbicki,Helmut Friess,Markus M. Lerch,Christos Dervenis,Attila Oláh,Giovanni Butturini,Ryuichiro Doi,Pehr Lind,David Smith,Juan W. Valle,Daniel H. Palmer,John A. C. Buckels,Joyce Thompson,Colin J. McKay,Charlotte L. Rawcliffe,Markus W. Büchler +26 more